Press Releases Gritstone bio, Inc.

Equities

GRTS

US39868T1051

Real-time Estimate Cboe BZX Other stock markets 01:01:53 2024-06-10 pm EDT			5-day change	1st Jan Change
0.747 ^USD	+0.19%		+1.20%	-63.57%

Jun. 01	Certain Restricted Stock Units of Gritstone bio, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2024.	CI
Jun. 01	Certain Stock Options of Gritstone bio, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pomerantz announces the filing of a class action lawsuit Gritstone bio, Inc. and Certain Officers - GRTS	Jun. 07	PR
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences	Jun. 04	AQ
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates	May. 09	GL
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024	May. 02	AQ
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024	Apr. 30	AQ
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors	Apr. 29	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	Apr. 20	PR
Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of 'Off-the-Shelf' Neoantigen Vaccine Platform	Apr. 16	AQ
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)	Apr. 15	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	Apr. 12	PR
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences	Apr. 08	AQ
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024	Apr. 08	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	Apr. 04	PR
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering	Apr. 01	AQ
Gritstone bio Announces Proposed Public Offering	Apr. 01	AQ
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)	Apr. 01	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	Mar. 19	PR
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates	Mar. 05	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	Mar. 04	PR
Gritstone bio Announces Workforce Reduction	Feb. 29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Gritstone bio, Inc.

Equities

GRTS

US39868T1051

Press Releases

Filters